Every one of those 1 sits in a single category, funding. Caleres is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Curis
Every one of those 1 sits in a single category, funding. Caleres is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 4 original sources on average, compared with 2.9 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6.3 for that window. Curis appears in 1 tracked Healthcare story from March 20, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Curis. Shared-story counts are live from our verified record — not editorial picks.
Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.